cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Homology Medicines Inc
8 own
17 watching
Current Price
$1.04
$0.05
(5.05%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
60.11M
52-Week High
52-Week High
3.3
52-Week Low
52-Week Low
0.86
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization60.11M
icon52-Week High3.3
icon52-Week Low0.86
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Homology Medicines Inc do?
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Read More
How much money does Homology Medicines Inc make?
News & Events about Homology Medicines Inc.
Globe Newswire
3 months ago
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development ...
Globe Newswire
3 months ago
PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term stockholders. Recently an amended securities fraud complaint was ...
Globe Newswire
3 months ago
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate inthe Gene Editing Corporate Panel during the 43rd Annual Cowen Healthcare ...
Ticker Report
4 months ago
Homology Medicines, Inc. (NASDAQ:FIXX Get Rating) has received a consensus rating of Moderate Buy from the ten brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have given a buy ...
Globe Newswire
5 months ago
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) on behalf of the Companys long-term investors. Recently an amended securities fraud complaint was filed against Homology on behalf of ...
Frequently Asked Questions
Frequently Asked Questions
What is Homology Medicines Inc share price today?
plus_minus_icon
Can Indians buy Homology Medicines Inc shares?
plus_minus_icon
How can I buy Homology Medicines Inc shares from India?
plus_minus_icon
Can Fractional shares of Homology Medicines Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Homology Medicines Inc stocks?
plus_minus_icon
What is today’s traded volume of Homology Medicines Inc?
plus_minus_icon
What is today’s market capitalisation of Homology Medicines Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Homology Medicines Inc?
plus_minus_icon
What percentage is Homology Medicines Inc down from its 52-Week High?
plus_minus_icon
What percentage is Homology Medicines Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.04
$0.05
(5.05%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.06
$-0.04 (-3.64 %)
IMMUNIC INC
IMMUNIC INC
$1.72
$0.10 (6.17 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.18
$0.04 (3.51 %)
Passage Bio Inc
Passage Bio Inc
$0.97
$-0.02 (-1.92 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.06
$-0.04 (-3.64 %)
IMMUNIC INC
IMMUNIC INC
$1.72
$0.10 (6.17 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.18
$0.04 (3.51 %)
Passage Bio Inc
Passage Bio Inc
$0.97
$-0.02 (-1.92 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00